At some time of PDUFA’s initial passage in 1992, some analysts lifted problems that introducing both of those user service fees along with a recurring should reauthorize their collection would undermine the agency’s independence from the regulated marketplace.ten On account of FDA’s budgetary dependence on marketplace user costs, marketplace